CU20170126A7 - Composiciones y métodos para tratar anemia - Google Patents

Composiciones y métodos para tratar anemia

Info

Publication number
CU20170126A7
CU20170126A7 CUP2017000126A CU20170126A CU20170126A7 CU 20170126 A7 CU20170126 A7 CU 20170126A7 CU P2017000126 A CUP2017000126 A CU P2017000126A CU 20170126 A CU20170126 A CU 20170126A CU 20170126 A7 CU20170126 A7 CU 20170126A7
Authority
CU
Cuba
Prior art keywords
anemia
compositions
methods
treat anemia
dialysis
Prior art date
Application number
CUP2017000126A
Other languages
English (en)
Spanish (es)
Inventor
Gurudatt Chandorkar
Ene Ikpong Ette
Ramin Farzaneh-Far
Charlotte Suzanne Hartman
Jula Kern Inrig
Bradley John Maroni
Alexander Smith
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57006457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20170126(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of CU20170126A7 publication Critical patent/CU20170126A7/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CUP2017000126A 2015-04-01 2016-03-31 Composiciones y métodos para tratar anemia CU20170126A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562141420P 2015-04-01 2015-04-01
US201562270168P 2015-12-21 2015-12-21
PCT/US2016/025235 WO2016161094A1 (en) 2015-04-01 2016-03-31 Compositions and methods for treating anemia

Publications (1)

Publication Number Publication Date
CU20170126A7 true CU20170126A7 (es) 2018-07-05

Family

ID=57006457

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000126A CU20170126A7 (es) 2015-04-01 2016-03-31 Composiciones y métodos para tratar anemia

Country Status (37)

Country Link
US (2) US11324734B2 (ko)
EP (2) EP3277270B1 (ko)
JP (3) JP6929785B2 (ko)
KR (2) KR102647879B1 (ko)
CN (2) CN107645953B (ko)
AU (3) AU2016243700B2 (ko)
BR (1) BR112017021097B1 (ko)
CA (1) CA2981176A1 (ko)
CL (2) CL2017002456A1 (ko)
CO (1) CO2017011200A2 (ko)
CR (2) CR20170450A (ko)
CU (1) CU20170126A7 (ko)
CY (1) CY1124869T1 (ko)
DK (1) DK3277270T3 (ko)
EA (1) EA036920B1 (ko)
EC (1) ECSP17073209A (ko)
ES (1) ES2900481T3 (ko)
HK (1) HK1248590A1 (ko)
HR (1) HRP20211862T1 (ko)
HU (1) HUE056958T2 (ko)
IL (3) IL292262B2 (ko)
LT (1) LT3277270T (ko)
MA (1) MA41863A (ko)
MX (3) MX2020009415A (ko)
MY (1) MY192705A (ko)
NZ (1) NZ735973A (ko)
PE (1) PE20180189A1 (ko)
PH (1) PH12017501789A1 (ko)
PL (1) PL3277270T3 (ko)
PT (1) PT3277270T (ko)
SA (1) SA517390054B1 (ko)
SG (1) SG11201707994UA (ko)
SI (1) SI3277270T1 (ko)
TW (4) TWI718138B (ko)
UA (1) UA123308C2 (ko)
WO (1) WO2016161094A1 (ko)
ZA (2) ZA201706681B (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4095127A1 (en) 2006-06-26 2022-11-30 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
NO2686520T3 (ko) 2011-06-06 2018-03-17
BR112015031027A2 (pt) 2013-06-13 2017-08-29 Akebia Therapeutics Inc Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem única
MX2021001169A (es) 2013-11-15 2023-02-10 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
BR112017015852A2 (pt) 2015-01-23 2018-03-27 Akebia Therapeutics Inc forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
IL292262B2 (en) 2015-04-01 2024-02-01 Akebia Therapeutics Inc Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid
JP6864834B2 (ja) * 2017-06-14 2021-04-28 ニプロ株式会社 投与量決定プログラムおよび投与量決定装置
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
MX2020011845A (es) 2018-05-09 2021-01-15 Akebia Therapeutics Inc Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
AU2020374963A1 (en) 2019-10-31 2022-06-09 Akebia Therapeutics, Inc. Therapeutic methods using vadadustat
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
KR20230017204A (ko) * 2020-04-29 2023-02-03 바이오에이지 랩스, 인코포레이티드 노화-관련 질환 치료용 저산소증-유도 인자 프롤릴 히드록실라제 억제제
KR20230027157A (ko) 2020-06-19 2023-02-27 아케비아 테라퓨틱스 인코포레이티드 바다두스타트의 약물-약물 상호작용의 조절
AU2022206302A1 (en) 2021-01-08 2023-08-17 Akebia Therapeutics, Inc. Therapeutic methods using vadadustat
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
IL305487A (en) 2021-03-01 2023-10-01 Akebia Therapeutics Inc Modulation of drug-drug interactions by VADADUSTAT

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
CA1261335A (en) 1984-08-29 1989-09-26 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Ethylenediamine monoamide derivatives
CN1023479C (zh) 1985-09-27 1994-01-12 弗·哈夫曼-拉罗切有限公司 乙二胺的单酰胺衍生物的制备方法
TW219933B (ko) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE59401924D1 (de) 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
EP0650960B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
JP2000509047A (ja) 1996-04-30 2000-07-18 ヘキスト・アクチエンゲゼルシヤフト ３―アルコキシピリジン―２―カルボキサミドエステル類、その製法および薬剤としてのその使用
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
US6420427B1 (en) 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2325471C (en) 1998-03-23 2010-08-17 Aventis Pharmaceuticals Products Inc. Piperididinyl and n-amidinopiperidinyl derivatives
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
SK12092002A3 (sk) 2000-03-22 2002-12-03 Pharmacia & Upjohn Formulácie tabliet obsahujúce oxazolidinóny
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
CN100522946C (zh) 2001-12-06 2009-08-05 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
EP1556033A4 (en) 2002-05-17 2006-05-31 Celgene Corp METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
KR20050033660A (ko) 2002-08-29 2005-04-12 머크 앤드 캄파니 인코포레이티드 Ｎ-바이아릴메틸 아미노사이클로알칸카복스아미드 유도체
EP1554394B1 (en) 2002-10-16 2009-12-16 Isis Innovation Limited Screening methods using a structural model of FIH
AU2003298611A1 (en) 2002-11-21 2004-06-18 Eli Lilly And Company Mixed lineage kinase modulators
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
PT1644336E (pt) 2003-06-06 2011-04-21 Fibrogen Inc Compostos de heteroarilo que contêm azoto e sua utilização no aumento da eritropoetina endógena
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
JPWO2005108370A1 (ja) 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
CA2567619A1 (en) 2004-05-28 2005-12-15 Fibrogen, Inc. Hif prolyl hydroxylase activity assay
WO2005115984A2 (en) 2004-05-31 2005-12-08 Tanabe Seiyaku Co., Ltd. Large conductance calcium-activitated k channel opener
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
DE05815688T1 (de) * 2005-01-27 2008-06-26 Alembic Ltd. Levetiracetam-formulierung mit verlängerter freisetzung
US20080213404A1 (en) 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
EP1893186A2 (en) 2005-06-06 2008-03-05 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
WO2006138511A2 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of hif 1alfa modulators for treatment of cancer
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
US20090176726A1 (en) 2005-10-11 2009-07-09 Fisher David E Methods for treating mitf-related disorders
US7728130B2 (en) 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
EP1971618A2 (en) 2006-01-09 2008-09-24 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
WO2007101204A1 (en) 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
TW200808793A (en) 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
ES2288117B1 (es) 2006-05-08 2008-12-01 Combino Pharm, S.L. Composicion farmaceutica solida de gabapentina.
WO2007136990A2 (en) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
PE20080209A1 (es) 2006-06-23 2008-05-15 Smithkline Beecham Corp Derivados de glicina como inhibidores de prolil hidroxilasa
EP4095127A1 (en) 2006-06-26 2022-11-30 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
CL2008000065A1 (es) 2007-01-12 2008-09-22 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
JP2008201711A (ja) * 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd システイン臭が低減された固形製剤
EP2136810A4 (en) 2007-04-18 2012-01-04 Merck Sharp & Dohme NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS
US7569726B2 (en) 2007-04-18 2009-08-04 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
ES2389063T3 (es) 2007-05-04 2012-10-22 Amgen, Inc Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
CN101678011B (zh) 2007-05-16 2012-07-18 默沙东公司 螺氮茚酮化合物
AU2008253311A1 (en) 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellshaft Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
JP5241718B2 (ja) 2007-08-06 2013-07-17 千寿製薬株式会社 ＨＩＦ−１αおよびＨＩＦ−２α発現阻害物質含有医薬
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
US20110028507A1 (en) 2007-08-10 2011-02-03 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
JP2011508725A (ja) 2007-11-30 2011-03-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
AU2008329746A1 (en) 2007-11-30 2009-06-04 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
EP2227475B1 (en) 2007-12-03 2014-02-19 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
WO2009086044A1 (en) 2007-12-19 2009-07-09 Smith Kline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
MY150481A (en) 2008-03-03 2014-01-30 Irm Llc Compounds and compositions as tlr activity modulators
PE20110409A1 (es) 2008-07-23 2011-06-22 Hoffmann La Roche Compuestos heterociclicos antiviricos
CN102149703B (zh) 2008-09-15 2014-09-10 卡斯娜莱拉伊诺制药私人有限公司 抗癌药物及将其用于治疗转移性恶性黑色素瘤及其他癌症
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
DK2415771T3 (da) 2009-03-31 2013-10-14 Kissei Pharmaceutical Indolizinderivat og anvendelse deraf til medicinske formål
CA2774046C (en) 2009-11-06 2014-01-21 Aerpio Therapeutics Inc. Compositions comprising n-benzyl or n-sulfonylaryl-3-hydroxypyridin-2-(1h)-ones and their use for treating colitis
JO2978B1 (en) 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids
US20140171465A1 (en) 2011-01-13 2014-06-19 Fibrogen, Inc. Methods For Increasing Reticulocyte Hemoglobin Content
CN103717214A (zh) 2011-06-06 2014-04-09 阿克比治疗有限公司 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
NO2686520T3 (ko) 2011-06-06 2018-03-17
WO2012174256A2 (en) 2011-06-17 2012-12-20 The Regents Of The University Of Michigan Dna methylation profiles in cancer
KR102029951B1 (ko) 2011-07-22 2019-11-08 베이징 베타 파머수티컬 컴퍼니 리미티드 프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도
WO2013070908A1 (en) 2011-11-09 2013-05-16 Fibrogen, Inc. Therapeutic method
WO2014075692A1 (en) 2012-11-19 2014-05-22 Azanta A/S Dispersible tablet
AU2014251038A1 (en) * 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
KR102291860B1 (ko) * 2013-06-06 2021-08-20 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
BR112015031027A2 (pt) 2013-06-13 2017-08-29 Akebia Therapeutics Inc Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem única
RU2016109125A (ru) 2013-08-16 2017-09-22 Огайо Стейт Инновейшн Фаундейшн Композиции и способы модуляции метилирования днк
MX2021001169A (es) 2013-11-15 2023-02-10 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
WO2015112831A1 (en) 2014-01-23 2015-07-30 Akebia Therapeutics, Inc. Compositions and methods for treating ocular diseases
US10617716B2 (en) 2014-12-16 2020-04-14 Urgo Us, Inc. Hypochlorous acid formulations and methods for treating skin conditions
BR112017015852A2 (pt) 2015-01-23 2018-03-27 Akebia Therapeutics Inc forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
WO2016153996A1 (en) 2015-03-20 2016-09-29 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
IL292262B2 (en) 2015-04-01 2024-02-01 Akebia Therapeutics Inc Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid

Also Published As

Publication number Publication date
US20230071553A1 (en) 2023-03-09
IL292262B2 (en) 2024-02-01
DK3277270T3 (da) 2021-12-06
AU2020273282A1 (en) 2020-12-17
TWI718138B (zh) 2021-02-11
ZA202006107B (en) 2024-02-28
LT3277270T (lt) 2022-01-10
PE20180189A1 (es) 2018-01-23
MA41863A (fr) 2021-06-02
ES2900481T3 (es) 2022-03-17
CN107645953A (zh) 2018-01-30
JP7270688B2 (ja) 2023-05-10
KR20170132865A (ko) 2017-12-04
CR20210248A (es) 2021-06-01
EP3277270B1 (en) 2021-10-27
CL2017002456A1 (es) 2018-04-20
EA201792182A1 (ru) 2018-06-29
IL254710A0 (en) 2017-11-30
CN115607521A (zh) 2023-01-17
CN107645953B (zh) 2022-11-01
KR102647879B1 (ko) 2024-03-15
US20180092892A1 (en) 2018-04-05
ECSP17073209A (es) 2017-12-01
EP3277270A4 (en) 2018-10-31
MX2017012460A (es) 2018-01-30
NZ735973A (en) 2023-06-30
IL292262A (en) 2022-06-01
MX2020009415A (es) 2021-10-04
AU2016243700B2 (en) 2020-08-20
AU2016243700A1 (en) 2017-10-26
SG11201707994UA (en) 2017-10-30
MX2021012155A (es) 2022-08-02
KR20240038132A (ko) 2024-03-22
IL254710B (en) 2022-05-01
AU2020273282B2 (en) 2022-10-20
TW202140001A (zh) 2021-11-01
TW202421140A (zh) 2024-06-01
TWI794725B (zh) 2023-03-01
JP2023093684A (ja) 2023-07-04
US11324734B2 (en) 2022-05-10
ZA201706681B (en) 2021-02-24
SI3277270T1 (sl) 2022-04-29
CO2017011200A2 (es) 2018-04-19
CR20170450A (es) 2018-04-03
MY192705A (en) 2022-09-02
PL3277270T3 (pl) 2022-02-14
CL2019001927A1 (es) 2019-11-29
BR112017021097A2 (pt) 2018-07-03
CA2981176A1 (en) 2017-10-06
HK1248590A1 (zh) 2018-10-19
CY1124869T1 (el) 2022-11-25
IL292262B1 (en) 2023-10-01
BR112017021097B1 (pt) 2024-01-02
EP3277270A1 (en) 2018-02-07
HRP20211862T1 (hr) 2022-03-04
EP3995138A1 (en) 2022-05-11
SA517390054B1 (ar) 2022-02-22
AU2023200252A1 (en) 2023-02-16
PT3277270T (pt) 2021-12-07
TW202320770A (zh) 2023-06-01
JP2021181478A (ja) 2021-11-25
PH12017501789A1 (en) 2018-04-11
UA123308C2 (uk) 2021-03-17
WO2016161094A1 (en) 2016-10-06
IL305910A (en) 2023-11-01
TWI836883B (zh) 2024-03-21
JP2018510178A (ja) 2018-04-12
EA036920B1 (ru) 2021-01-15
HUE056958T2 (hu) 2022-04-28
TW201642839A (zh) 2016-12-16
US11844756B2 (en) 2023-12-19
JP6929785B2 (ja) 2021-09-01

Similar Documents

Publication Publication Date Title
CL2017002456A1 (es) Composiciones y métodos para el tratamiento de la anemia.
ECSP20058592A (es) Composiciones y métodos para tratar anemia
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila
BR112018013847A2 (pt) métodos para administrar a angiotensina ii
AR104157A1 (es) Composiciones y métodos para el tratamiento de la anemia
CL2016001361A1 (es) Regimen de dosificación para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa
CR20150660A (es) Composiciones y metodos para tratar anemia
BR112018070526A2 (pt) tratamento do carcinoma de células renais com lenvatinibe e everolimo
BR112017021589A2 (pt) métodos para o tratamento de transtornos cardiovasculares
EA201991517A1 (ru) Композиции и способы ингибирования активности аргиназы